Jeffrey Aronin on pharmaceutical industry
From Berson Lecture | Jeff Aronin, Life Sciences Innovator | Full Lecture and Q&A · · Center for the Study of Human Health | Emory Univ.
“Big pharmaceutical companies grow by buying other companies but struggle to innovate internally. They focus on incremental improvements in big markets, but often ignore smaller opportunities like rare diseases. Entrepreneurial companies can innovate in these underserved areas because they don't have the same infrastructure constraints.”
On , Jeffrey Aronin, Founder & Non-Executive Chairman at HARMONY BIOSC HOLD INC, spoke about pharmaceutical industry during Berson Lecture | Jeff Aronin, Life Sciences Innovator | Full Lecture and Q&A on Center for the Study of Human Health | Emory Univ..
About Jeffrey Aronin
Jeffrey Aronin, founder and non-executive chairman of Harmony Biosciences, delivered a lecture in September 2020 in which he discussed his work at the intersection of life sciences and entrepreneurship. He stated that his companies focus on developing treatments for patients with diseases that have no existing therapies, and that they have obtained multiple FDA approvals. Aronin noted that only about 50 drugs are approved annually in the United States, and that many drug companies do not recoup their investment. He emphasized the importance of aligning with investors who provide long-term capital, given the unpredictable nature of scientific outcomes. Aronin also discussed the potential of artificial intelligence in healthcare, saying that AI will change the entire system in the coming years. He mentioned that his companies have developed an AI diagnosis tool for breast cancer that received FDA approval. He described gene therapy as an area where the majority of future drug approvals will occur, and noted that manufacturing remains the most challenging aspect. Aronin highlighted the underfunding of antibiotic development and the issue of patient non-compliance with medication, both of which he said contribute to higher healthcare costs.